多虑平治疗慢性病贫血的机制研究

丁芳, 吴振添, 吴良华, 等. 多虑平治疗慢性病贫血的机制研究[J]. 临床血液学杂志, 2016, 29(3): 216-218. doi: 10.13201/j.issn.1004-2806.2016.03.012
引用本文: 丁芳, 吴振添, 吴良华, 等. 多虑平治疗慢性病贫血的机制研究[J]. 临床血液学杂志, 2016, 29(3): 216-218. doi: 10.13201/j.issn.1004-2806.2016.03.012
DING Fang, WU Zhentian, WU Lianghua, et al. An in vivo assay for doxepin in treating anemia of chronic disease[J]. J Clin Hematol, 2016, 29(3): 216-218. doi: 10.13201/j.issn.1004-2806.2016.03.012
Citation: DING Fang, WU Zhentian, WU Lianghua, et al. An in vivo assay for doxepin in treating anemia of chronic disease[J]. J Clin Hematol, 2016, 29(3): 216-218. doi: 10.13201/j.issn.1004-2806.2016.03.012

多虑平治疗慢性病贫血的机制研究

  • 基金项目:

    宁德市科技计划项目(No:20150060)

    福建省自然科学基金资助项目(No:闽科计[2015]15号)

详细信息
    通讯作者: 何云绮,E-mail:943946824@qq.com
  • 中图分类号: R556.9

An in vivo assay for doxepin in treating anemia of chronic disease

More Information
  • 目的: 探讨多虑平治疗大鼠慢性病贫血(ACD)的机制。方法: 将24只大鼠按照随机对照原则共分为3个组:健康对照组、ACD模型组、多虑平治疗组,每组均为8只。药物治疗1周后采集新鲜血液,用自动化血液分析仪测定血常规,ELISA法检测血清中IL-6浓度;取肝组织,用RT-PCR法检测肝脏hepcidin mRNA表达量。结果: ACD模型组血清中IL-6水平、肝脏hepcidin mRNA表达量较健康对照组显著升高(P<0.01),且分别与血红蛋白呈线性负相关(r=-0.591、r=-0.759),肝脏hepcidin mRNA 表达量与血清IL-6水平呈线性正相关(r=0.619)。多虑平治疗组血清IL-6水平、肝脏hepcidin mRNA表达量较ACD模型组均显著下降(P<0.05),血红蛋白明显升高(P<0.01)。结论: 多虑平可改善大鼠ACD,作用机制可能与其通过抑制IL-6水平、降低hepcidin mRNA表达量有关。
  • 加载中
  • [1]

    Qiu MZ,Yuan ZY,Luo HY,et al.Impact of pretreatment hematologic profile on survival of cliorectal cancer patients[J].Tumour Biol,2010,31:255-260.

    [2]

    Zhang Y,Chen Y,Chen D,et al.Impact of preoperative anemia on relapse and survival in breast cancer patients[J].BMC Cancer,2014,14:844.

    [3]

    Rainville N,Jachimowicz E,Wojchowski DM.Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis[J].Expert Opin Ther Targets,2015,30:1-15.

    [4]

    孙雪峰,周道斌,赵永强.EPO对铁调蛋白hepcidin表达影响的研究[J].中国实验血液学杂志,2006,14(4):778-782.

    [5]

    Eleftheriadis T,Pissas G,Antoniadi G,et al.Kynurenine,by activating aryl hydrocarbon receptor,decreases erythropoietin and increases hepcidin production in HepG2 cells:a new mechanism for anemia of inflammation[J].Exp Hematol,2016,44:60-67.

    [6]

    Vokurka M,Krijt J,Vávrová J,et al.Hepcidin expression in the liver of mice with implanted tumour reacts to iron deficiency,inflammation and erythropoietin administration[J].Folia Biol (Praha),2011,57:248-254.

    [7]

    Altschuler EL,Kast RE.Using histamine (H1) antagonist,in particular atypical antipsychotics,to treat anemia of chronic disease via interleukin-6 suppression[J].Med Hypotheses,2005,65:65-67.

    [8]

    Richelson E.Antimuscarinic and other receptor-blocking properties of antidepressants[J].Mayo Clin Proc,1983,58:40-46.

    [9]

    Ganz T.Hepcidin and iron regulation,10 years later[J].Blood,2011,117:4425-4433.

    [10]

    Rishi G,Wallace DF,Subramaniam VN.Hepcidin:regulation of the master iron regulator[J].Biosci Rep,2015,35:e00192.

    [11]

    Jiang F,Yu WJ,Wang XH,et al.Regulation of hepcidin through GDF-15 in cancer-related anemia[J].Clin Chim Acta,2014,428:14-19.

    [12]

    Przybyszewska J,Zekanowska E.The role of hepcidin,ferroportin,HCP1,and DMT1 protein in iron absorption in the human digestive tract[J].Prz Gastroenterol,2014,9:208-213.

    [13]

    王恒石,胡喜梅,周水阳,等.血清TNF-α、IFN-γ、IL-6水平与慢性病贫血的关系[J].山东医药,2014,54(45):79-81.

    [14]

    Hohaus S,Massini G,Giachelia M,et al.Anemia in Hodgkin's lymphoma:the role of interleukin-6 and hepcidin[J].J Clin Oncol,2010,28:2538-2543.

    [15]

    Akdis CA,Blaser K.Histamine in the immune regulation of allergic inflammation[J].J Allergy Clin Immunol,2003,112:15-22.

    [16]

    Masuda K,Kimura A,Hanieh H,et al.Aryl hydrocarbon receptor negatively regulates LPS-induced IL-6 production through suppression of histamine production in macrophages[J].Int Immunol,2011,23:637-645.

  • 加载中
计量
  • 文章访问数:  222
  • PDF下载数:  140
  • 施引文献:  0
出版历程
收稿日期:  2015-12-25

目录